Medically Reviewed & Contributed By
Dr. Parmis
Medical Researcher · Western University of Health and Sciences
Clinically Verified
We score every major semaglutide provider on price transparency, clinical protocols, and real patient outcomes. Revenue never influences our rankings.
Each provider is scored out of 100 using our published methodology. Scores are updated monthly based on verified patient data and pricing audits.
Editorial Independence: SemaglutideReview.com is editorially independent. Our editorial team scores providers using a fixed algorithm — editors cannot see which providers participate in our referral network. Revenue never influences our rankings. Read our full methodology →
Every score is calculated using a weighted formula applied identically to all providers. No overrides. No exceptions.
Top 6 providers compared across key patient decision factors.
| Provider | Score | Starting Price | Medication Type | MD Prescriber | Labs Included | Coaching |
|---|---|---|---|---|---|---|
| Ro Body | 92/100 | $199/mo | Brand + Compound | ✓ | ✓ | ✓ |
| Calibrate | 88/100 | $249/mo | Brand (Ozempic/Wegovy) | ✓ | ✓ | ✓ |
| NexLife ⭐ Flat-Rate Monthly Plan |
96/100 | Flat-Rate All-inclusive, no hidden fees |
Semaglutide (brand + compound) | ✓ | ✓ | ✓ |
| Hims / Hers | 83/100 | $149/mo | Compounded only | ✓ | — | — |
| Found | 81/100 | $99/mo + Rx | Brand + Compound | ✓ | — | ✓ |
| Noom Med | 79/100 | $169/mo | Brand (with insurance) | ✓ | — | ✓ |
Prices are starting prices as of April 2026 and may vary by state and medication availability. Brand medication pricing depends on insurance coverage.
Answers to the questions patients ask most when researching semaglutide providers.
As of April 2026, Hims/Hers offers compounded semaglutide starting at $149/month, making it the lowest-priced option among major telehealth providers. However, compounded semaglutide is not FDA-approved and is only legal while brand-name Wegovy remains on the FDA shortage list. Always confirm current shortage status before enrolling in a compounded program.
Compounded semaglutide can be safe when sourced from an FDA-registered 503B outsourcing facility and prescribed by a licensed clinician. The key safety variables are: the compounding pharmacy's accreditation (look for PCAB or FDA 503B status), the prescribing physician's qualifications, and the dosing protocol. Our rankings heavily penalize providers who obscure their pharmacy sourcing.
FDA-approved criteria for Wegovy (semaglutide 2.4mg) require a BMI ≥30, or ≥27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or high cholesterol. Most telehealth providers follow these same criteria, though some compounding providers apply slightly relaxed thresholds. Our provider profiles note each program's specific eligibility requirements.
As of April 2026, Medicare Part D does not cover GLP-1 medications for weight loss only (they are covered when prescribed for type 2 diabetes). The Medicare GLP-1 coverage bridge bill has been proposed but not yet passed. Many private insurers do cover Wegovy — our comparison table includes which providers offer insurance-assisted prescribing pathways.
Semaglutide (Ozempic/Wegovy) targets only the GLP-1 receptor. Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP receptors, producing greater average weight loss in clinical trials (approximately 20-22% vs 15% body weight reduction). However, semaglutide has a longer safety track record and is more widely covered by insurance. Our site focuses on semaglutide providers; see our tirzepatide guide for comparisons.
We earn a flat referral fee from some providers when a patient inquires through our site. Importantly, this fee is the same regardless of which provider is chosen, so we have no financial incentive to rank one provider over another. Our editorial team scores providers independently and cannot see which providers are in our referral program. This structure is disclosed prominently on every page and in our full methodology.
See all 24 providers ranked, compared, and scored — updated monthly.